Cited by 357Monoclonal and Polyclonal Antibodies ResearchProtein purification and stabilityImmune Cell Function and Interaction

The DOI matches its Crossref record; 94 of the 95 references it cites were found in a registry or an index.

IgG Fc engineering to modulate antibody effector functions

Open access

Wang, Xinhua, Mathieu, Mary, Brezski, Randall J.·2018·Protein & Cell

DOI 10.1007/s13238-017-0473-8PMC PMC5777978

Open this paper in CoChat — free account Open PDF

Abstract

Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An important aspect of antibodies is their ability to bind antigen while at the same time recruit immune effector functions. The majority of approved recombinant monoclonal antibody therapies are of the human IgG1 subclass, which can engage both humoral and cellular components of the immune system. The wealth of information generated about antibodies has afforded investigators the ability to molecularly engineer antibodies to modulate effector functions. Here, we review various antibody engineering efforts intended to improve efficacy and safety relative to the human IgG isotype. Further, we will discuss proposed mechanisms by which engineering approaches led to modified interactions with immune components and provide examples of clinical studies using next generation antibodies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s13238-017-0473-8

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 The Fc domain of human IgG1 is shown (PDBID:3AVE). The positions of amino acids described in Table 1 are shown. Key sequence motifs for FcRn interactions are shown in green (L251-S254; L309-Q311; N434-H435) (Oganesyan et al., 2014). Amino acids 5 angstroms proximal to the FcγR:Fc interface for FcγRI (PDBID:4W4O) (Kiyoshi et al., 2015), FcγRIIa (PDBID:3RY6) (Ramsland et al., 2011), FcγRIIb (PDBID:3WJJ) (Mimoto et al., 2013b), and FcγRIIIb (PDBID:1E4K) (Sondermann et al., 2000) as determined with PyMOL are shown in red (P232-S239; D265-D270; Y296-T299; N325-I332). The amino acids that are critical for interactions with C1q are shown in blue (D270, K322, P329, P331) (Idusogie et al., 2000). Amino acids depicted in black were not identified as critical for interactions with FγRs, FcRn, or C1q. Figure 1 was generated with PyMOL.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
Cartron, G., Dacheux, L., Salles, G. A., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,954
Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2014) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,369
High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,172
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature reviews. Immunology · doi:10.1038/nri1837 · Cited by 1,124
THE COVALENT STRUCTURE OF AN ENTIRE γG IMMUNOGLOBULIN MOLECULE
Edelman, G. M., Cunningham, B. A., Gall, W. E., Gottlieb, P. D., Rutishauser, U. S., & Waxdal, M. J. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.63.1.78 · Cited by 903
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C. S. C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 824

Show all 95 references

Sorted by citations

Items 301–357 of 357

Conception de protéines bimodulaires réorientant une réponse anticorps préexistante vers des cellules pathogéniques
Chêne, A., Teillaud, J., Viatte, L., & Gamain, B. (2022) · médecine/sciences · doi:10.1051/medsci/2022135
Protein Therapeutics
Leach, M. W., & Hammerman, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00024-5
Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
Boustany, L. M., LaPorte, S. L., Wong, L., White, C. W., Vinod, V., Shen, J., Yu, W., Koditek, D., Winter, M. B., Moore, S. J., et al. (2023) · doi:10.1158/0008-5472.c.6514182.v1
Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
Boustany, L. M., LaPorte, S. L., Wong, L., White, C. W., Vinod, V., Shen, J., Yu, W., Koditek, D., Winter, M. B., Moore, S. J., et al. (2023) · doi:10.1158/0008-5472.c.6514182
Data from Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
Rossmueller, G., Mirkina, I., Maurer, B., Hoeld, V., Mayer, J., Thiele, M., Kerschbaumer, R. J., & Schinagl, A. (2023) · doi:10.1158/1535-7163.c.6603184.v1
Antibody effector functions are required for broad and potent protection of neonates from herpes simplex virus infectionPreprint
Slein, M. D., Backes, I. M., Garland, C. R., Kelkar, N. S., Leib, D. A., & Ackerman, M. E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.29.555423
Effects of Fc glycosylation on the activity of WNT mimetic agonistic antibodies
Chen, H., Lee, S., Ouyang, B., Suen, N., Ye, J., Lu, C., & Li, Y. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbae002
MODULATION OF IMMUNITY AND BARRIER FUNCTION IN PRE- AND POSTNATAL ANIMAL ONTOGENESIS. PHYSIOLOGICAL ASPECTS OF NATURAL RESISTANCE IN SOWS
Masiuk, D. M., Nedzvetsky, V. S., & Кокарєв, А. В. (2023) · doi:10.30525/978-9934-26-395-8-12
Study on the S239D/I332E mutation effect on the kinetics of Fc–Fc receptor binding through transition complex theory
Jebamani, P., & Lee, S. (2024) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-024-00104-7
Topical delivery of human single-domain antibody targeting IL-33 for inhibiting mucosal inflammationPreprint
Ying, T., Huang, K., Wu, Y., Kong, Y., Xu, Q., Zhang, Y., Li, Q., Li, C., Song, W., Zhu, X., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4975440/v1
Ligands and carriers for enhancing immune activity: Mechanisms of action and prospects for applications in medicine and biotechnology
Gogina, S. S., & Stoynova, A. M. (2023) · Medical Immunology (Russia) · doi:10.15789/1563-0625-lac-2894
Harnessing Natural Killer Cells for Cancer Therapy
Rajalingam, R. (2025) · Springer eBooks · doi:10.1007/978-3-030-80962-1_194-1
Innate Immune Cell Engagers: Matchmakers for Next-Generation Immunotherapy
Cording, S., Pahl, J. H. W., Ellwanger, K., Breunig, C., & Koch, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_37-1
Biomembrane structure at the molecular level and its application in precision medicine
Wang, Z., Tian, Z., Gao, J., & Wang, H. (2025) · Biophysics Reviews · doi:10.1063/5.0213964
Targeting Anti-HLA Class I and II Antibodies with CAR-B Cell Therapy: A Novel Strategy to Mitigate Graft Rejection and Platelet RefractorinessPreprint
Kesherwani, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.20.639042
Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers
Drouin, A., Durand, L., Esnault, C., Gaboriaud, P., Leblond, V., Karim, S. M. M., Fouché, M., Dhommée, C., Baltus, C. B., Boursin, F., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010897
Beyond IgG: Novel Insights into IgA and IgM Glycosylation in Tuberculosis and Their Role in Differentiating Infection StatusPreprint
Yang, Y.-J., Lee, C., Chuang, Y., Wang, S., Chen, M. X., Shih, H., & Tsai, I. (2025) · Research Square · doi:10.21203/rs.3.rs-6381409/v1
Pharmacokinetics, Pharmacodynamics, and Safety of Nipocalimab in Healthy Chinese Volunteers: A Single-Dose, Phase I Study
Li, H., Liu, J., Wang, X., Zhao, W., Zhang, L., Niu, X., Liu, J., & Dong, Z. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00763-5
Self-citation
Receptomics and Extracellular Interactomics for Biotherapeutic Characterization
Chandan, N. R., Ferrel, A., & Cao, S. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch17
Light Chain Isotype and Antibody-Specificity Impact on Virus Neutralization
Sun, L., Palt, R., Schütz, G., Föderl-Höbenreich, E., Brod, L., Hermle, A., Lux, A., Steinkellner, H., & Kallolimath, S. (2025) · Antibodies · doi:10.3390/antib14020050
Integrated Glycosylation Analysis of Immunoglobulin Isotypes Reveals Expanded Humoral Remodeling in Elderly Tuberculosis Infection
Yang, Y.-J., Lee, C., Wang, S., Chuang, Y., Chen, M. X., Shih, H., & Tsai, I. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101438
Changes in the Interaction Properties of Antibodies with Fc Receptors upon Binding to Target Antigens
Grevtsev, A. S., Kommer, A. A., Zelmanchuk, I. S., Avdiushkin, A. S., Ermolaeva, E. O., Tiulin, A. A., Chernyshova, D. O., Azarian, A. D., Gordeev, A., & Misorin, A. K. (2025) · Biosensors · doi:10.3390/bios15110759
Impacts of Antibody Structure and Mixtures on Receptor Signaling for Antibody-Dependent Cellular Cytotoxicity
Guan, J., Wang, T., Tessier, P. M., & Thurber, G. M. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01183-x
Additional file 1 of Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus
Seyfizadeh, N., Kalbermatter, D., Imhof, T., Ries, M., Müller, C., Jenner, L., Blumenschein, E., Yendrzheyevskiy, A., Grün, F., Moog, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25918902
Additional file 1 of Harnessing ceramic hydroxyapatite as an effective polishing strategy to remove product- and process-related impurities in bispecific antibody purification
Ingavat, N., Wang, X., Liew, J. M., Mahfut, F. B., But, K. P., Kok, Y. J., Bi, X., Yang, Y., Shintaro, K., Tsoumpra, M. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26653401
Self-citation
Additional file 1 of Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives
Xu, H., Shi, M., Shao, C., Li, H., Wu, J., Yu, Y., Fang, F., Guo, Y., & Xiao, W. (2021) · Figshare · doi:10.6084/m9.figshare.14759862
A potent protein vaccines OmpW induces strong protective immunity against Klebsiella pneumoniae in a mouse model
Huang, T., Che, S., Zhang, H., Jiang, W., Hao, D., Lv, Z., Yu, Y., Zhang, Y., Yang, R., Luo, L., et al. (2026) · Medical Microbiology and Immunology · doi:10.1007/s00430-026-00867-1
Microsecond Dynamics of Fc–CD16a Recognition: Impact of Mutations, Core Fucosylation, and Fc Asymmetry
Estaran, S., Hehlen, B., & Chavanieu, A. (2026) · Antibodies · doi:10.3390/antib15010017
Comparison of IgG1 and IgG4: A Structural and Molecular Perspective
Nirmal, D. N., & Kulkarni, S. (2026) · Applied Research · doi:10.1002/appl.70086
Polypharmacology of S-1117, an Fc-fused IgG-selective degrading enzyme, for chronic treatment of autoantibody-mediated diseases
Sanmarco, L. M., Pellerin, A., Green, T., Plasencia, A., Anderson, J. M., Le, N., Newton, A., Chen, J. S., Ramello, M. C., Peckner, R., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2518366123
Inhibitory receptor agonists: Emerging strategies in immune modulation
Adam, K. R., Suhail, A., Kuchroo, V. K., & Vignali, D. A. A. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20241217
Ciblage de la protéase cathepsine D par des anticorps monoclonaux humains pour la thérapie des cancers du sein triple-négatifs
Mansouri, H. (2018) · theses.fr (ABES) · doi:10.70675/2e06ebdbz7834z420bz9202zfcefe4f3791a
Mechanical forces in the binding of single domain antibodies developed for therapeutics : from molecular to cellular response
Gutierrez, C. G. (2018) · doi:10.70675/526cf393z077ez41c3za7f1zbf7f29c5d1ef
Mise en oeuvre de microréseaux de lectines naturelles et recombinantes dédiés au suivi de production des glycoprotéines d'intérêt thérapeutique
Machon, O. (2019) · theses.fr (ABES) · doi:10.70675/603bc1c9z03f9z4582zbbb3z053819e4e2c7
Un nouveau type d'anticorps bispécifique avec une activité de déplétion ciblée de facteurs solubles pro-tumoraux du microenvironnement tumoral pour la thérapie du cancer
Laroche, A. (2019) · theses.fr (ABES) · doi:10.70675/738719b7z2e18z405fz9d79z9ecf8c822cf2
Caractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2
Dufloo, J. (2021) · theses.fr (ABES) · doi:10.70675/215798eaz7f82z4e57za8eazf4453d37b8c8
Etude des mécanismes de contrôle des cellules tumorales par les cellules Natural Killer
Fenis, A. (2024) · theses.fr (ABES) · doi:10.70675/747c59caz7a79z4064z989cz9dd2bc8bd27e
Identification de gènes impliquées dans la régulation de la lyse tumorale médiée par les cellules NK par un crible pangénomique avec la technologie CRISPR-CAS9
Khlifi, H. M. (2024) · doi:10.70675/657a9bfbz9ff4z4b10z9482z849ee105d5c5
Antibodies against Neuromuscular Blocking agents in allergic patients : from mechanisms to therapeutics
Dejoux, A. (2024) · doi:10.70675/89367e48zeaaaz4df4z89c8zd79e955328d6
FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy
Marei, H. E. S., Pozzoli, G., Caratelli, S., & Cenciarelli, C. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04258-7
Engineering nasally delivered IgM antibodies for respiratory viral infections
Ramesh, A. K., & An, Z. (2026) · hLife · doi:10.1016/j.hlife.2026.03.004
Development and validation of a semi-automated hybrid immunocapture liquid chromatography-mass spectrometry method to quantify LALA-mutated biotherapeutics in mouse plasma
Papa, V., Salve, I. D., Molinaro, F., Ianni, A. D., Monge, S., Mastroianni, R., Ariaudo, A., Tavano, P., Castagna, V., Cowan, K. J., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107540
Small intestine-permeable cyclic peptide-mediated enhancement of Fc-fusion protein absorption in mice
Chikamatsu, S., Sakaguchi, K., Sasaki, K., Ohtsuki, S., & Ito, S. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104335
Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials
Jansen, E., Bockstal, V., Herschke, F., Gisleskog, P. O., Rinaldi, M., Boerboom, A., Hadi, S., Gaibu, N., Moutschen, M. P., & Tersago, D. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004609
Development of single-chain C1q affinity chromatography–mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions
Lippold, S., Chang, K., Dürkoop, M., Andersen, J. T., Yang, F., & Schlothauer, T. (2026) · mAbs · doi:10.1080/19420862.2026.2687922
Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study
Vissing, J., Pease, S., Scippa, K., Gandhi, K., Ramchandren, S., Grover, K. M., Huang, D., & Watanabe, G. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13978-9
Bispecific Antibody‐Based Combination Therapies for B‐Cell Lymphomas: Current Evidence and Future Perspectives
Cheng, M., Li, W., Liu, M., & Zou, L. (2026) · International Journal of Cancer · doi:10.1002/ijc.70602
Novel biopharmaceutical strategies: Fc-fusion protein technology
Ding, X.-Y., Fan, H.-L., Zhang, C., Wei, M.-X., Lin, Z.-Z., Bai, C.-J., Wang, M. M., & Zhou, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1853458
Protective monoclonal antibody targeting mycobacterial HBHA blocks the interaction with the novel attachment co-receptor NRP1 to inhibit Mycobacterium bovis entry
Qu, M., Zhou, X., Zhang, X., Chenggang, J., Zhang, Z., Hu, S., Xiao, F., Quan, X., Ge, X., Bu, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.08.042
Fc-engineering for improved cancer immunotherapy
Borgman, E., Gall, C. M. L., Ploegh, H. L., & Pishesha, N. (2026) · Biochemical Society Transactions · doi:10.1042/bst20250554
αHSA-proIL-12: A Tumor-Conditional IL-12 Prodrug with Reduced Systemic Toxicity and Potent Antitumor Activity
Wang, X., Yang, L., Hou, Y., Wang, G., Ding, Y., Zhang, Y., Wang, S., & Hong, Z. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177716
Self-citation
Mitigating HER2-targeted antibody‒drug conjugate-induced interstitial lung disease through Fc-region glycosylation engineering
Yang, Y., Xing, Y., Zhang, J., Dai, Y., Ma, L. B., Yang, T., Li, Y., Li, Y., Zhang, J., Wang, Y., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.005
Human and porcine IgG subclasses differentially engage porcine Fc receptors
Vats, A., May, C., Moorhouse, E., Lokhman, E., Crossley, S., Hay, A., Placido, M. B., Graham, S. P., Rijal, P., Townsend, A., et al. (2026) · Discovery Immunology · doi:10.1093/discim/kyag018
Low dose chidamide promotes inhibitory Fcγ receptorIIb expression on monocytes in ITP: A translational study of human ITP samples and ITP murine models
Zhao, H., Liu, W., Wang, H., Li, D., Su, C., Sun, M., Liu, X., Sun, L., Wang, J., Qiu, X., et al. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261491619
Impact of time and temperature on glycation, oxidation, and functional stability of trastuzumab deruxtecan (ENHERTU®) in dextrose infusion bags
Hindes, E., Cochard, V., Fourati, S., Bendiab, Y. M., Juul, C., Combeau, D., Yagoubi, N., Chevreux, G., Antignac, M., & Yayé, H. S. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107680
Computational design and translational development of TCR-mimic scFv antibodies for peptide-HLA neoantigen targeting
Niazi, S. K., Magoola, M., & Mariam, Z. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00084-z
Engineered antibodies: the molecular workhorses of the immune system as therapeutics
Singh, A., Shadangi, S., Bag, S., & Rana, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44536-1.00017-1

Authors: Wang, X., Mathieu, M., & Brezski, R. J.
Affiliations: Genentech (US)
Corresponding author: Brezski, Randall J.
ORCID: Wang, Xinhua
Brezski, Randall J.
Venue: Protein & Cell
Publisher: Oxford University Press (OUP)
Published: 2017-10-06
Volume: 9
Issue: 1
Pages: 63-73
ISSN: 1674-800X (ISSN-L)
1674-8018
DOI: 10.1007/s13238-017-0473-8
PMC: PMC5777978
OpenAlex: W2763907629
Cited by: 356
References: 95
Citations by year: 2026: 28 · 2025: 41 · 2024: 57 · 2023: 35 · 2022: 50 · 2021: 44 · 2020: 44 · 2019: 43 · 2018: 13 · 2017: 1
FWCI: 4.22
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (unspecified)
Locations: Protein & Cell (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Keywords: antibody effector functions, human IgG1, therapeutic monoclonal antibodies, antibody engineering, immune effector mechanisms, antibody safety, antibody efficacy
MeSH terms: Animals, Antibodies, Monoclonal, Antigens, Complement System Proteins, Humans, Immunoglobulin G, Receptors, Fc, Protein Engineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

IgG Fc engineering to modulate antibody effector functions

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks